Featured

‘Extraordinary’ cancer treatment breakthrough sees 94% of patients go into remission

A new breakthrough in cancer treatment has triggered a staggering 94 percent remission rate during one trial.

Image: John Liebler (Flickr)

A new breakthrough in cancer treatment is being hailed as “revolutionary” by scientists after reports of “unprecedented success” from an immunotherapy treatment that triggered a staggering 94 percent remission rate during one trial.

The procedure, which turns a patient’s own cells into tumor-killing agents, was first announced at the 2016 meeting of the American Association for the Advancement of Science in Washington DC earlier in the week.

The most impressive results came from a group of 35 patients with acute lymphoblastic leukemia who saw the 94 percent remission rate result.

From The Guardian:

More than 40 patients with lymphoma have also been treated, with remission rates of more than 50%. In a group with non-Hodgkin’s lymphoma, there was evidence of diminished cancer symptoms in more than 80% of cases.

“This is unprecedented in medicine, to be honest, to get response rates in this range in these very advanced patients,” project’s researcher Stanley Riddell said.

Recent advances in genetic engineering has allowed scientists to realize new ways of exploiting T cells in the human body, while boosting their innate abilities to specifically target cancerous tumors.

According to IFLS, researchers have engineered T cells to make receptors that recognize a molecule called CD19, which is almost exclusively found on another type of white blood cell called the B cell, destroying tumors originating from these cells such as certain lymphomas and leukemias.

Doctors then remove immune cells from a cancer patient, then “tag” the cell with a “receptor” molecule that targets a specific cancer, similar to how T-cells target the flu or infections. They then infuse the cells back into the patient.

“These are in patients that have failed everything. Most of the patients in our trial would be projected to have two to five months to live,” said project researcher Chiara Bonini. “T-cells are a living drug, and in particular they have the potential to persist in our body for our whole lives.”

“Much like chemotherapy and radiotherapy, it’s not going to be a save-all,” Riddell said. “I think immunotherapy has finally made it to a pillar of cancer therapy.”

Facebook Comment
5 Comments

5 Comments

  1. Brettrew

    June 10, 2017 at 2:36 pm

    wh0cd3408083 STERAPRED DS

  2. 176559 419347you make blogging glance 209659

  3. see post

    June 23, 2017 at 8:03 am

    I just want to say I am beginner to blogging and honestly enjoyed you’re blog site. Almost certainly I’m want to bookmark your site . You actually have great posts. With thanks for revealing your website.

  4. have a peek at this web-site

    June 30, 2017 at 3:12 pm

    It is actually mostly close to impossible to come across well-aware people on this theme, still, you appear like you understand the things you’re preaching about! Regards

  5. visit this page

    June 30, 2017 at 3:21 pm

    Genuinely intriguing information you’ll have said, thank you so much for posting.

Leave a Reply

Your email address will not be published.

To Top